HWAN-JEONG JEONG | Cancer Cell Biology | Best Researcher Award

Posted on by sciencefather

Prof. Dr. HWAN-JEONG JEONG | Cancer Cell Biology | Best Researcher Award

Prof. Dr. WAN-JEONG JEONG , Department of Nuclear Medicine, Molecular Imaging Therapeutic Medicine Research Center, Jeonbuk Regional Cyclotron Research Center & Biotracer Imaging Lab. Jeonbuk National University Medical School & Hospital, South Korea

Dr. Hwan-Jeong Jeong is a distinguished leader in the field of nuclear medicine, currently serving as Director and Professor at Jeonbuk National University Medical School & Hospital, South Korea. With over two decades of academic and clinical experience, Dr. Jeong has pioneered research in molecular imaging, photobiomodulation, and radiopharmaceutical science. He has made impactful contributions to translational oncology, neuroimaging, and light-based therapeutics. With over 120 peer-reviewed publications, 33 patents, and an H-index of 44, his work bridges the gap between basic science and clinical innovation. Recognized for advancing image-guided therapy and precision diagnostics, he also actively collaborates across global institutions and serves as Associate Editor for Nuclear Medicine and Molecular Imaging. A recipient of multiple national and international recognitions, Dr. Jeong’s efforts continue to shape the future of medical imaging and cancer therapeutics. His commitment to integrating engineering and medicine marks him as a global innovator in nuclear and molecular medicine.

Publication Profile:

Orcid

✅ Strengths for the Award:

  • Outstanding Academic and Clinical Background: Dr. Jeong holds an MD, a Master’s in Medical Engineering, and a PhD in Medicine, with postdoctoral training at the prestigious MD Anderson Cancer Center.

  • Leadership in Research: As Director of multiple research centers, he has led over 20 high-impact projects, overseen 5 industry collaborations, and contributed to 120+ SCI-indexed publications.

  • Innovation & Translation: Holder of 33 patents, Dr. Jeong is a pioneer in integrating photobiogoverning, PET/CT imaging, and light-based cancer therapy, bridging lab discoveries and clinical application.

  • Global Recognition: Editorial board role in Nuclear Medicine and Molecular Imaging, and a consistent H-index of 44, reflect international impact and scientific credibility.

  • Cutting-Edge Contributions: Known for novel developments in blue light phototherapy, tumor-targeted radiopharmaceuticals, and noninvasive neuroimaging, significantly advancing cancer and neurological diagnostics.

⚠️ Areas for Improvement:

  • Broader International Collaboration: While highly respected in Korea and internationally, formalizing more international co-research programs or multicenter trials could further expand global reach.

  • Public Engagement & Science Communication: Increasing public visibility through science outreach, open-access publications, or global lectures/webinars can elevate the societal impact of his research.

  • Interdisciplinary Expansion: Potential to integrate AI-based imaging analysis or bioinformatics tools into existing molecular imaging and diagnostics research may boost next-gen innovation.

🎓 Education:

Dr. Hwan-Jeong Jeong began his academic journey at Chonnam National University, where he earned his MD in 1993, followed by a Master’s in Medical Engineering in 2000, and a Ph.D. in Medicine in 2003. He pursued his residency in Nuclear Medicine at Chonnam National University Hospital, gaining a strong clinical foundation. To further enhance his research capabilities, he completed a prestigious postdoctoral fellowship at MD Anderson Cancer Center, University of Texas, Houston, between 2008–2010. His educational path reflects an interdisciplinary approach—blending clinical medicine, biomedical engineering, and advanced imaging sciences. With an emphasis on nuclear medicine and optical diagnostics, Dr. Jeong’s educational background has strategically positioned him at the intersection of clinical practice and high-impact research. His academic evolution reflects a consistent dedication to innovation, translational research, and global collaboration.

🧪 Experience:

Dr. Jeong has served as Director and Professor of Nuclear Medicine at Jeonbuk National University Medical School & Hospital since 2005. His professional journey began with clinical training and residency, evolving into a global research career that includes a pivotal postdoctoral role at MD Anderson Cancer Center. Over the years, he has directed more than 20 research projects, consulted on 5 industry collaborations, and published over 120 scientific papers. Dr. Jeong holds 33 patents, highlighting his innovation in photomedicine and molecular imaging. He leads multiple advanced imaging centers and research labs, including the Molecular Imaging Therapeutic Medicine Research Center and Jeonbuk Regional Cyclotron Research Center. Internationally respected, he also serves as an Associate Editor for Nuclear Medicine and Molecular Imaging. His experience combines clinical expertise, leadership in research infrastructure, and international collaborations that foster innovation and patient-centered imaging solutions.

🔬 Research Focus:

Dr. Jeong’s research lies at the nexus of nuclear medicine, molecular imaging, and photobiomodulation therapy. His groundbreaking work integrates blue light phototherapy, PET/CT molecular imaging, radiopharmaceutical development, and fiber-optic–guided treatment systems for cancers and neurological disorders. He has made significant advances in FDG-PET imaging, amyloid brain scans, and light-triggered tumor therapies, facilitating precision diagnostics and targeted interventions. A key innovator in photobiogoverning—the biological control via light—Dr. Jeong has translated preclinical concepts into clinical applications through rigorous trials and device validation. His projects often explore the interface between biomedical optics and nano-diagnostics, enhancing real-time monitoring and minimally invasive treatments. Through cross-disciplinary collaborations and cutting-edge device design, he has shaped protocols that merge imaging with therapy for high-impact patient outcomes. His research aligns closely with future directions in personalized medicine and oncology imaging.

📚 Publications Top Notes:

  • 📘 From molecular mechanisms to clinical applications: A comprehensive review of photobiomodulation in cancer treatment

  • 📘 Blue-light activated nanoplatforms for image-guided cancer therapy

  • 📘 Clinical applications of brain amyloid PET imaging in neurodegenerative diseases

  • 📘 Multimodal theranostics using PET/CT and photodynamic therapy in head and neck cancer

  • 📘 Innovative radiotracers for monitoring tumor hypoxia and therapeutic response

  • 📘 Fiber-optic–based interstitial phototherapy in liver malignancies: A pilot clinical study

  • 📘 Nanomedicine-based nuclear imaging in virus-infected tissues

  • 📘 Bioluminescent imaging in evaluating immunotherapy response in solid tumors

  • 📘 Therapeutic implications of photobiogoverning in minimally invasive oncology

  • 📘 Noninvasive tracking of neuroinflammation using fluorinated PET probes

🧾 Conclusion:

Dr. Hwan-Jeong Jeong is an exceptionally qualified nominee for the Best Researcher Award. His contributions to nuclear medicine, molecular imaging, and light-based therapies exemplify academic excellence, clinical innovation, and translational impact. His body of work aligns closely with the award’s values—scientific rigor, real-world application, and forward-thinking medical solutions. With ongoing work in precision diagnostics and phototherapy, he not only meets but exceeds the standards expected of top global researchers in biomedical science. Dr. Jeong’s profile is a model of interdisciplinary leadership, making him a compelling and well-deserved recipient for this prestigious recognition.

Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Posted on by sciencefather

Mr. Wei Xue | Cancer Cell Biology | Best Academic Researcher Award

Mr. Wei Xue , Renji Hospital, School of Medicine, Shanghai Jiaotong University , China

Dr. Xue Wei, M.D., Ph.D., is a distinguished urologist, professor, and researcher specializing in genitourinary oncology. Currently serving as the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, he also leads its Department of Urology. With over 150 publications, including 100+ SCI-indexed papers, Dr. Xue is a leading expert in minimally invasive urological surgeries, particularly robotic-assisted procedures. He has made significant contributions to prostate cancer treatment and multidisciplinary approaches for metastatic prostate cancer. Dr. Xue is an executive member of various prestigious medical organizations, including the Chinese Medical Association and the European Association of Urology. His groundbreaking research and clinical excellence have earned him multiple accolades, including “Shanghai Leading Talent” and “Outstanding Academic Leader.” With a strong dedication to advancing medical technology and patient care, Dr. Xue continues to shape the future of urological oncology through his pioneering work in surgery, research, and mentorship.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Research Contributions 📚 – Dr. Xue Wei has over 150 publications, including 100+ SCI-indexed papers, highlighting his impactful work in genitourinary oncology.

  2. Leadership & Influence 🌍 – As Vice President of Renji Hospital and Director of Urology, he plays a crucial role in shaping the future of urological research and treatment.

  3. Clinical Expertise 🏥 – He is an expert in robot-assisted and minimally invasive surgeries, particularly nerve-sparing radical prostatectomy and multidisciplinary management of metastatic prostate cancer.

  4. High-Impact Research Grants 💰 – Principal investigator for 12 key research projects, including those funded by the National Natural Science Foundation of China.

  5. Prestigious Recognitions 🏆 – Titles like Shanghai Leading Talent and Outstanding Academic Leader reflect his excellence in academia and clinical practice.

📌 Areas for Improvement:

  1. Citations & Impact Factor Growth – While his publication count is high, increasing citations and impact factor of his papers would further establish global recognition.

  2. Global Collaboration – Expanding international partnerships and multicenter clinical trials could enhance his research influence beyond China.

  3. Innovative Breakthroughs – While excelling in robotic-assisted surgery, pioneering novel therapeutic strategies could further elevate his status as a global thought leader.

🎓 Education:

Dr. Xue Wei completed his M.D. and Ph.D. in Urology at Shanghai Jiao Tong University School of Medicine, a premier institution in China known for its rigorous medical training and research excellence. He further honed his expertise through international academic collaborations, including a tenure as a Visiting Associate Professor at the MD Anderson Cancer Center, USA. His academic journey was marked by intensive research in genitourinary oncology, robotic-assisted surgeries, and advanced treatment modalities for prostate and renal cancers. Over the years, he has received advanced training in minimally invasive urological surgery, leveraging cutting-edge technology to improve surgical outcomes. His strong academic foundation, combined with a commitment to innovation, has made him a globally recognized expert in urological oncology. Through continuous education and research leadership, Dr. Xue remains at the forefront of medical advancements, ensuring his contributions have a lasting impact on both clinical practice and scientific research.

💼 Experience:

Dr. Xue Wei boasts a distinguished career spanning decades in clinical practice, research, and academic leadership. He is the Vice President of Renji Hospital, Shanghai Jiao Tong University School of Medicine, and Director of its Department of Urology. As a key figure in the Chinese and international urology communities, he holds executive positions in prestigious organizations such as the Chinese Medical Association, European Association of Urology, and American Urological Association. Dr. Xue specializes in minimally invasive and robotic-assisted urological surgeries, pioneering advanced techniques in radical prostatectomy and cancer treatment. His leadership extends to mentoring doctoral students and overseeing high-impact research projects funded by national and municipal grants. His role as a principal investigator in groundbreaking studies has led to over 150 peer-reviewed publications. With his clinical expertise, surgical innovations, and research contributions, Dr. Xue remains a leader in shaping the future of urological oncology.

🏆 Awards & Honors:

Dr. Xue Wei has earned numerous prestigious accolades in recognition of his contributions to urological research and clinical excellence. Among his most notable honors are:

  • Shanghai Leading Talent 🌟

  • Outstanding Academic Leader, Shanghai 🏅

  • Shanghai Medical Leading Talent 🎖️

  • Shanghai Craftsman & Shanghai Medical Craftsman 🏆

As a globally recognized expert, Dr. Xue’s pioneering work in robotic-assisted surgery and genitourinary oncology has solidified his reputation as a leading academician and clinician. His dedication to advancing minimally invasive surgery and cancer treatment has not only influenced medical practice in China but also gained international recognition. He serves as a mentor and research leader, shaping the next generation of urologists. With his exceptional achievements, Dr. Xue continues to set benchmarks in urological science, making him a strong contender for the Best Academic Researcher Award.

🔬 Research Focus:

Dr. Xue Wei’s research primarily focuses on genitourinary oncology, with a particular emphasis on prostate cancer, kidney cancer, and minimally invasive surgery. He has led multiple high-impact studies on robot-assisted laparoscopic procedures, multidisciplinary management of metastatic prostate cancer, and biomolecular mechanisms of cancer progression. His work in precision medicine and targeted therapies has contributed to advancements in prostate cancer treatment, enhancing survival outcomes and treatment efficacy.

As the principal investigator of 12 research projects funded by the National Natural Science Foundation of China and the Shanghai Municipal Education Commission, Dr. Xue has pushed the boundaries of medical innovation. His recent research explores the role of m6A RNA modifications, immunotherapy, and cancer stem cells in drug resistance and tumor aggressiveness. His contributions have transformed clinical practices, bridging the gap between cutting-edge research and real-world patient care, making him a global leader in urological oncology research.

📚 Publications Top Notes:

  1. AGD1/USP10/METTL13 Complexes Enhance Cancer Stem Cells Proliferation and Diminish the Therapeutic Effect of Docetaxel 🔬🧬

  2. Specific Activation of cGAS-STING Pathway by Manganese-Doped Bioactive Glasses for Boosting Systemic Tumor Immunotherapy 🏥🧪

  3. Osalmid Sensitizes Clear Cell Renal Cell Carcinoma to Navitoclax Through a STAT3/BCL-XL Pathway 🏥💊

  4. Efficacy and Predictive Factors Analysis of Androgen Deprivation Plus Novel Hormone Therapy as Neoadjuvant Treatment for High-Risk Prostate Cancer 🔎⚕️

  5. Open Nephron-Sparing Surgery Strategy for Renal Angiomyolipoma with Vena Cava Thrombus 🏥🔬

  6. A Phase II Study of Tislelizumab as Neoadjuvant Treatment for Cisplatin-Ineligible High-Risk Upper Tract Urothelial Carcinoma 💉🔬

  7. Proportion of Gleason Score ≥8 Prostate Cancer on Biopsy and Tumor Aggressiveness in East Asian vs. Non-East Asian Men 🧬🧑‍⚕️

  8. Iron-Loaded Cancer-Associated Fibroblasts Induce Immunosuppression in Prostate Cancer 🩸🛡️

  9. A Multi-Classifier System Integrated by Clinico-Histology-Genomic Analysis for Predicting Recurrence of Papillary Renal Cell Carcinoma 🏥📊

🏅 Conclusion:

Dr. Xue Wei is a highly suitable candidate for the Best Academic Researcher Award due to his exceptional contributions in urological oncology, leadership in clinical research, and dedication to innovation. His extensive academic output, surgical expertise, and impact on medical education make him a leading figure in his field. Enhancing global collaborations and high-impact publications would further solidify his legacy as a world-class researcher. 🚀